{"entity":{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","aka":["Yingli Pharma"],"tldr":"Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.","summary":"Shanghai Yingli Pharmaceutical is a small-molecule company in Shanghai's Zhangjiang science park. Its PI3K-delta inhibitor linperlisib (YY-20394) received conditional NMPA approval in November 2022 for relapsed or refractory follicular lymphoma after two or more lines, and is in trials in peripheral T-cell lymphoma and solid tumours.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.yingli-pharma.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["linperlisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai, China","country":"CN","companyType":"biotech","website":"https://www.yingli-pharma.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/shanghai-yingli/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/"}],"trial":[{"id":"nct04379167","kind":"trial","name":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct04379167/"},{"id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","route":"/trials/nct06662669/"}]}}